Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic ...

Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® ...

US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending ...

Market OverviewThe Global Hormone Replacement Therapy Market is valued at USD 22.6 Billion in 2023 and is projected to reach ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the ...

Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...

Shares of Septerna sank to their lowest level yet after the company said it would end the phase 1 clinical trial for SEP-786 as a treatment for hypoparathyroidism. The stock fell 68% to a low of $4.17 ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

The decision to halt the trial was made despite the lack of serious adverse events or indications of liver injury, cholestasis, or hemolysis in trial participants. Septerna's CEO, Jeffrey Finer, ...